Aker BioMarine announced that it is significantly expanding its research commitment in the krill marketplace. As part of this effort, eight new scientists will join the company this month to broaden the knowledge and understanding of krill, with a particular focus on clinical outcomes and new product applications.
The new team is comprised of several individuals with expertise in R&D, regulatory affairs and product development. They include Finn Myhren, PhD, R&D; Wenche Rasch, PhD, R&D; Petter-Arnt Hals, PhD, R&D; Stefan Hupfeld, PhD, R&D; Tore Duvold, PhD, R&D; Trygve Bergeland, PhD, R&D; Hanne Loken, PhD, Regulatory Affairs; and Tove Flem Jacobsen, MSc, R&D.
"Aker BioMarine has always been committed to investing in krill research - this is the next logical step in that direction," said Tim de Haas, vice president of business development. "This is a substantial investment that will give us the internal resources we need to follow through on some of the development ideas we have and deliver what the market is asking for."
An improved consumer experience (i.e., smaller capsules, no fishy burps, better tolerability, etc.) for nutrients essential to better health has fueled krill's solid double-digit growth in each of the past few years, making it the fastest growing segment in the omega-3 category. This is creating new opportunities for greater product diversification and application.
Matts Johansen, chief operating officer of Aker BioMarine, commented: "From research and development to clinical studies to regulatory and market execution, this is a seasoned group of scientists that have worked many years in successful professional environments. They are just what we need to follow through on our big plans for Superba Krill."